These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27306811)

  • 1. [A Retrospective Analysis of Epiphora Due to Docetaxel].
    Noguchi Y; Kawashima Y; Kawara H; Tokuyama Y; Tamura Y; Uchiyama K; Shimizu Y
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):737-41. PubMed ID: 27306811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epiphora in lung cancer patients receiving docetaxel: a case series.
    Yamagishi T; Ochi N; Yamane H; Hasebe S; Takigawa N
    BMC Res Notes; 2014 May; 7():322. PubMed ID: 24886618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of excessive tearing as a side effect of docetaxel.
    Esmaeli B
    Clin Breast Cancer; 2005 Feb; 5(6):455-7. PubMed ID: 15748466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel.
    Esmaeli B; Amin S; Valero V; Adinin R; Arbuckle R; Banay R; Do KA; Rivera E
    J Clin Oncol; 2006 Aug; 24(22):3619-22. PubMed ID: 16877729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin for palliative treatment of epiphora in a patient with canalicular obstruction.
    Tu AH; Chang EL
    Ophthalmology; 2005 Aug; 112(8):1469-71. PubMed ID: 15953639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.
    Esmaeli B; Hortobagyi G; Esteva F; Valero V; Ahmadi MA; Booser D; Ibrahim N; Delpassand E; Arbuckle R
    Ann Oncol; 2002 Feb; 13(2):218-21. PubMed ID: 11885997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity.
    Tsalic M; Gilboa M; Visel B; Miller B; Haim N
    Med Oncol; 2006; 23(1):57-61. PubMed ID: 16645230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.
    Esmaeli B; Hortobagyi GN; Esteva FJ; Booser D; Ahmadi MA; Rivera E; Arbuckle R; Delpassand E; Guerra L; Valero V
    Ophthalmology; 2002 Jun; 109(6):1188-91. PubMed ID: 12045065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect.
    Esmaeli B; Valero V; Ahmadi MA; Booser D
    Ophthalmology; 2001 May; 108(5):994-5. PubMed ID: 11320034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel-associated epiphora.
    Kintzel PE; Michaud LB; Lange MK
    Pharmacotherapy; 2006 Jun; 26(6):853-67. PubMed ID: 16716138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
    Esmaeli B; Hidaji L; Adinin RB; Faustina M; Coats C; Arbuckle R; Rivera E; Valero V; Tu SM; Ahmadi MA
    Cancer; 2003 Aug; 98(3):504-7. PubMed ID: 12879466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
    Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M
    JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis.
    Leyssens B; Wildiers H; Lobelle JP; Gillis A; Paridaens R; Mombaerts I
    Ann Oncol; 2010 Feb; 21(2):419-423. PubMed ID: 19622592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and Management of Chemotherapy-Induced Epiphora, Punctal and Canalicular Stenosis, and Nasolacrimal Duct Obstruction.
    Mansur C; Pfeiffer ML; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2017; 33(1):9-12. PubMed ID: 27429222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy.
    Chan A; Su C; de Boer RH; Gajdatsy A
    J Clin Oncol; 2013 Jun; 31(17):2123-7. PubMed ID: 23650421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
    Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
    Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important?
    Esmaeli B; Valero V
    J Clin Oncol; 2013 Jun; 31(17):2076-7. PubMed ID: 23650413
    [No Abstract]   [Full Text] [Related]  

  • 18. Botulinum neurotoxin injection for the treatment of epiphora in nasolacrimal duct obstruction.
    Girard B; Piaton JM; Keller P; Abadie C; Nguyen TH
    J Fr Ophtalmol; 2017 Oct; 40(8):661-665. PubMed ID: 28847443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect.
    Kalra R; Chavada B; Madhani NR; Purohit B; Tripathi CB
    Curr Drug Saf; 2018; 13(1):62-64. PubMed ID: 28933276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
    Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
    Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.